The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL), for treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The AJMC asked Precision’s Erin Lopata to weigh in on how to respond when a drug is added to NCCN guidelines before the FDA approves the indication.
The Administration’s recently released final rule on transparency in healthcare coverage is set to take effect January 1, 2023. The rule aims to provide increased visibility into the cost of care for treatments and procedures and to support cost-conscious decisions about healthcare services. Precision’s Erin Lopata provides an overview of what you need to know now.
Update on HHS drug pricing rules: An HHS final rule targeting Medicare Part D rebates was issued on November 30, 2020. Unlike the interim rule, the final rule includes only rebates in Part D, not Medicaid managed care, and it pushes back implementation from Jan. 1, 2020, to Jan. 1, 2022. Comments on the interim final rule following the Most Favored Nation model are due by Jan. 26, 2021. Precision’s Andrew Cournoyer and Ryan Cox weigh in on the problems and concerns with both rules.
The COVID-19 pandemic consumed most of 2020. While it was the big story last year, it wasn’t the only story. Precision’s Dan Danielson and other experts weigh in on the oversized impact of COVID-19 on the pharma industry, and other trends from 2020.
Value-based care has been replacing the traditional fee-for-service model in the United States. Value-based care models and population health are essential to improving health and reducing health care costs. Precision’s Ryan Cox discusses how value-based payment models in chronic kidney disease can improve total cost and quality of care for patients.
Does COVID-19 Threaten the Progress Pharmaceuticals Have Made in Reducing Cancer Mortality Over the Last 20 Years?
While the development and introduction of new pharmaceuticals have played a pivotal role in reducing US cancer deaths, winning the war on cancer is a multifaceted battle. Meanwhile, COVID-19 has affected virtually every aspect of cancer care, from the research and development of new therapies, to diagnosis and treatment.
An interim final rule that would require pricing drugs on the U.S. market based on their prices in certain countries is set to take effect on Jan. 1, 2021. Industry experts claim it will have little effect on bringing down prices for consumers. Precision’s Ryan Cox joins other experts in discussing the far ranging impact of the new rule.
Research suggests that new cancer treatments have played an especially important role in reducing mortality rates in certain cancers over the past several decades. Disruption to the industry from the COVID-19 pandemic threatens this progress.
In an effort to increase patient access to affordable drugs, California recently created Cal Rx, a state-sponsored generic prescription drug label. Precision’s Jason Shafrin weighs in on the potential impact the law ultimately will have. Precision’s Jason Shafrin weighs in on the potential impact the law ultimately will have.